News coverage about Bellerophon Therapeutics (NASDAQ:BLPH) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bellerophon Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.1479417659204 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- A quick recap Technical data on Bellerophon Therapeutics, Inc. (BLPH) – Wall Street Morning (wallstreetmorning.com)
- uniQure NV (QURE) registers a price change of 1.40% while Bellerophon Therapeutics, Inc. (BLPH) – Stocks Gallery (stocksgallery.com)
- BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares – SEC filing (reuters.com)
- Protagonist Therapeutics, Inc. (PTGX) is at $16.25 per share and Bellerophon Therapeutics, Inc. (BLPH) is listed at … – Stocks Gallery (stocksgallery.com)
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) opened at 1.36 on Thursday. Bellerophon Therapeutics has a 12 month low of $0.43 and a 12 month high of $1.68. The stock’s market cap is $48.29 million. The firm has a 50-day moving average price of $1.34 and a 200-day moving average price of $1.34.
Bellerophon Therapeutics (NASDAQ:BLPH) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Equities analysts forecast that Bellerophon Therapeutics will post ($1.12) EPS for the current year.
A number of brokerages have commented on BLPH. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research report on Friday, September 15th. ValuEngine upgraded Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 8th. Finally, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th.
COPYRIGHT VIOLATION NOTICE: “Bellerophon Therapeutics (BLPH) Getting Somewhat Positive Press Coverage, Analysis Shows” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2017/10/26/bellerophon-therapeutics-blph-getting-somewhat-positive-press-coverage-analysis-shows.html.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.